• Capricor Therapeutics announced that the FDA has lifted its prior Complete Response Letter and resumed review of the Biologics License Application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy, assigning a Class 2 resubmission with a PDUFA target action date of August 22, 2026.
• This renewed review, combined with Deramiocel’s multiple regulatory designations and a commercialization agreement with Nippon Shinyaku for the U.S. and Japan, reshapes how investors may view Capricor’s path toward potential market entry in rare disease cardiomyopathy.
• Against this backdrop, we will examine how the renewed FDA review timeline for Deramiocel influences Capricor Therapeutics’ broader investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

What Is Capricor Therapeutics' Investment Narrative?

For anyone considering Capricor, the core belief is that Deramiocel can move from an investigational therapy to a commercial rare disease product, transforming a small, loss-making biotech into a revenue-focused company. The FDA’s decision to lift its Complete Response Letter and restart the BLA review, with a new August 22, 2026 PDUFA date, puts regulatory risk back at the center of the story and effectively extends the catalyst timeline. Near term, attention is likely to pivot to how Capricor funds operations during this extended review window, how it executes on its partnership with Nippon Shinyaku for U.S. and Japan, and how investors weigh the current valuation after a very large multi‑year share price run. The business still hinges heavily on a single asset and one pivotal regulatory outcome.

However, investors should be aware that funding needs and single‑asset reliance remain critical risks. Capricor Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six Simply Wall St Community fair value estimates span roughly US$31 to US$263 per share, underscoring how differently individual investors are pricing Deramiocel’s risk and reward. Set against the renewed FDA review timeline and Capricor’s reliance on a single lead asset, these divergent views highlight why you may want to compare several perspectives before deciding how the story fits into your portfolio.

Explore 6 other fair value estimates on Capricor Therapeutics - why the stock might be worth over 7x more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.